Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.

Abstract

BACKGROUND:

The combination of carboplatin and docetaxel has been considered one of the standard treatments for advanced non-small cell lung cancer (NSCLC). To investigate a safer and more convenient schedule for outpatient, we conducted a phase II study to evaluate the efficacy and the safety of carboplatin plus biweekly docetaxel for advanced NSCLC.

PATIENTS AND METHODS:

Patients with stage IIIB, IV, or postoperative recurrent NSCLC with good performance status were administered docetaxel at a dose of 35 mg/m on days 1 and 15 and carboplatin at an area under the curve (AUC) of 6 on day 1 every 4 weeks for at least three cycles.

RESULTS:

Fifty patients were treated with median of three cycles (range 1-6). Grade 3/4 toxicities included neutropenia in 18 patients (36%), thrombocytopenia in 4 patients (8%), and anemia in 10 patients (20%). No patient experienced febrile neutropenia. Nonhematological toxicities were also mild to moderate, and there were no treatment-related deaths. The overall response rate was 30%, and the disease control rate was 70%. Among the elderly population, 54% of patients achieved partial response. Median progression-free survival was 4.8 months, and median overall survival was 11.8 months.

CONCLUSIONS:

Biweekly docetaxel plus carboplatin has a similar efficacy and lower toxicity compared with a standard triweekly regimen of docetaxel plus carboplatin, which is a suitable regimen for outpatients, including elderly patients.

• Authors: Osamu Ishimoto, Shunichi Sugawara, Akira Inoue, Takashi Ishida, Mitsuru Munakata, Sadahiro Koinumaru, Yukihiro Hasegawa, Toshiro Suzuki, Hiroshi Miki, Yasuo Saijo, Toshihiro Nukiwa
• Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 1 Issue 9 Pg. 979-83 (Nov 2006) ISSN: 1556-1380 [Electronic] United States
• PMID: 17409982 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• Taxoids
• Docetaxel
• Carboplatin

Topics

• Adult
• Age Factors
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Carboplatin (administration & dosage, adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, pathology)
• Disease-Free Survival
• Docetaxel
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Infusions, Intravenous
• Lung Neoplasms (drug therapy, mortality, pathology)
• Male
• Maximum Tolerated Dose
• Middle Aged
• Neoplasm Invasiveness (pathology)
• Neoplasm Staging
• Risk Factors
• Survival Analysis
• Taxoids (administration & dosage, adverse effects)